A tough-minded executive known for visionary leadership in high growth and under-performing businesses and for his leadership in corporate governance.
Larry G. Stambaugh is a principal at Apercu Consulting where he serves as an advisor to several private and public boards and CEOs, concentrating on strategic business direction, turnarounds and board governance. He is currently working with clean tech and life science teams to help them raise capital, reach their highest levels of achievement, uncover sensitive issues and generate superior options for action. Using 30+ years of successful problem solving and leadership to bring clarity and help focus teams on facing and conquering the tough challenges, including appropriately defining themselves, gaining financing, and driving products to the market.
He presently serves as the Chairman of the Board of Cryoport, inc., Chairman & CEO of Ridge Diagnostics, Director at EcoDog, Board member and Executive Committee of BioCom and Board member and Executive Committee of the Corporate Directors Forum.
During his more than 35-year career Mr. Stambaugh has faced and solved many of the toughest business problems that can challenge a company. As a top executive his visionary leader has built management teams and companies around “A humble heart and an open mind”.
He has led the turnaround of organizations through setting strategic initiatives with the board and management for new directions and priorities. His well developed process has effectively guided the board and management to realistically access their strengths and weakness and direct the organization into new businesses and discontinue under-performing activities and business units.
Mr. Stambaugh has raised nearly $400 million of capital in private and public financing. He has taken a company public in both the U.S. and Europe. In times of weak financing markets he has found creative alternatives for financing including, PIPE transactions, syndicated bank loans, reverse mergers, corporate collaborations and private equity funding.
Well ahead of his time, Mr. Stambaugh has had a focus on board activities and corporate governance practices for nearly three decades. He has more than 75 years of board service and speaks on the best practices and current issues in corporate governance. In 2002, 2006 and again in 2007 he was awarded the “Director of the Year” recognition for his work in corporate governance leadership and education. He has worked with numerous boards and their directors to make the board a strategic asset of the company and improve the working relationship between management and the board. Mr. Stambaugh founded and leads one of the most highly acclaimed national corporate governance meetings each year.
He was recently conducted a turn around as the Chief Executive Officer and President of Calando Pharmaceuticals, a biotechnology company working in the field of nanotechnology and messenger RNA on innovative treatments for cancer and other diseases. He was the former Chairman, CEO and co-founder for Maxim Pharmaceuticals, Inc. At Maxim he established a public, global biopharmaceutical company with a pipeline of product candidates for life-threatening cancers and liver diseases. He merged Maxim with an East Coast biotech company in 2006. A drug for AML, the most common adult leukemia, that was developed by Maxim, was approved following the merger. Previously, he was the Chairman, President and CEO for ABC Laboratories, a world-leading environmental research laboratory serving Fortune 100 pharmaceutical and chemical companies. Mr. Stambaugh has worked as a top executive in banking, manufacturing, retail and began his career at KPMG.
He has a B.B.A. from Washburn University and is a C.P.A. He is married to Pamela Stambaugh and has five children and four grandchildren.